1. Home
  2. EDBL vs JAGX Comparison

EDBL vs JAGX Comparison

Compare EDBL & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

HOLD

Current Price

$1.21

Market Cap

4.0M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.34

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDBL
JAGX
Founded
2020
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
3.9M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
EDBL
JAGX
Price
$1.21
$1.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
66.7K
116.3K
Earning Date
11-14-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,553,000.00
$11,785,000.00
Revenue This Year
$29.56
$22.41
Revenue Next Year
$20.00
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.45
52 Week Low
$1.05
$1.10
52 Week High
$13.50
$33.25

Technical Indicators

Market Signals
Indicator
EDBL
JAGX
Relative Strength Index (RSI) 43.23 34.48
Support Level $1.05 $1.10
Resistance Level $1.25 $1.98
Average True Range (ATR) 0.12 0.16
MACD 0.01 -0.03
Stochastic Oscillator 60.00 25.00

Price Performance

Historical Comparison
EDBL
JAGX

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: